Fortuna Mining Corp. Common Shares vs Liquidia Corporation Common Stock — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.42 (market cap $3.12B), while Liquidia Corporation Common Stock trades at $34.26 (market cap $2.40B). The key difference: Fortuna Mining Corp. Common Shares is the larger of the two by market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 6 Days and Liquidia Corporation Common Stock for 0 Days on average.
| FSM | LQDA | |
|---|---|---|
Market Cap | $3.12B | $2.40B |
Volume | 2,648,950 | 2,857,547 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $91.03 |
52-Week Low | $7.84 | $22.02 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $2.74B | $2.30B |
Signals from Pluang's Aura AI — not financial advice
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →